PDGFRA DI842-843VM

pdgfra d842突变的特点是伊马替尼耐药突变。DI842-843VM变异体是双点突变的结果。这在胃肠道间质瘤中表现最为明显，但含有这些突变的其他细胞系也表现出抗药性。在伊马替尼耐药细胞系中，许多其他治疗方法已证明有效。这些包括：克雷诺拉尼、西罗莫司和中龙血素（pkc412）。
PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. The DI842-843VM variant is the result of a double point mutation. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).